← Eichor
Condition: Diffuse Midline Glioma H3 K27M Mutant Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Diffuse Midline Glioma H3 K27M Mutant

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Combination Therapy for the Treatment of Diffuse Midline Gliomas
Phase 2 · 32 location(s) · University of California, San Francisco · NCT05009992FUS Etoposide for DMG
Phase 1 · 1 location(s) · Columbia University · NCT05762419Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Phase 1 · 2 location(s) · Emory University · NCT06624371Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Phase 1 · 7 location(s) · Sabine Mueller, MD, PhD · NCT04732065Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Phase 3 · 50 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT05476939Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial
Phase 2 · 2 location(s) · Mayo Clinic · NCT05077735rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Phase 1 · 3 location(s) · Ann & Robert H Lurie Children's Hospital of Chicago · NCT04943848Targeted Pediatric High-Grade Glioma Therapy
Phase N/A · 21 location(s) · Nationwide Children's Hospital · NCT05839379CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children a
Phase 1 · 1 location(s) · OX2 Therapeutics · NCT06305910ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Phase 3 · 162 location(s) · Jazz Pharmaceuticals · NCT05580562CAR T Cells to Target GD2 for DMG
Phase 1 · 1 location(s) · University College, London · NCT05544526Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Phase 2 · 20 location(s) · Nationwide Children's Hospital · NCT05843253Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Phase 1 · 1 location(s) · Jazz Pharmaceuticals · NCT04541082Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 202
Phase N/A · 42 location(s) · European Organisation for Research and Treatment of Cancer - · NCT05259605International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository
Phase N/A · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT03101813A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pon
Phase 2 · 1 location(s) · Guangzhou Virotech Pharmaceutical Co., Ltd. · NCT07589257Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT07076498
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.